Verve Therapeutics Inc. Announces Delisting from Nasdaq Following Merger Completion

Reuters2025-07-26
<a href="https://laohu8.com/S/VERV">Verve Therapeutics</a> Inc. Announces Delisting from Nasdaq Following Merger Completion

Verve Therapeutics Inc. has announced a regulatory development regarding its listing status. On July 23, 2025, the company notified the Nasdaq Stock Market LLC of its impending merger and requested the suspension of trading of its common stock, effective by the close of business on July 24, 2025. Additionally, Verve Therapeutics has asked Nasdaq to file a Form 25 with the SEC to delist and deregister its common stock under Section 12(b). This action follows the completion of the merger agreement, leading to significant changes in the company's board of directors and termination of several definitive agreements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verve Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-165462), on July 25, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment